Literature DB >> 16110290

Probability of axillary lymph node metastasis when sentinel lymph node biopsy is negative in women with clinically node negative breast cancer: a Bayesian approach.

Takahiro Okamoto1, Kiyomi Yamazaki, Masako Kanbe, Hitomi Kodama, Yoko Omi, Akiko Kawamata, Rumi Suzuki, Yuka Igari, Reiko Tanaka, Masatoshi Iihara, Yukio Ito, Tatsuo Sawada, Toshio Nishikawa, Masako Maki, Kiyoko Kusakabe, Norio Mitsuhashi, Takao Obara.   

Abstract

BACKGROUND: Although sentinel lymph node biopsy(SLNB)is highly accurate in predicting axillary nodal status in patients with breast cancer, it has been shown that the procedure is associated with a few false negative results. The risk of leaving metastatic nodes behind in the axillary basin when SLNB is negative should be estimated for an individual patient if SLNB is performed to avoid conventional axillary lymph node dissection(ALND).
METHODS: A retrospective analysis of 512 women with T1-3N0M0 breast cancer was conducted to derive a prevalence of nodal metastasis by T category as a pre-test(i.e., before SLNB)probability and to examine potential confounders on the relationship between T category and axillary nodal involvement. Probability of nodal metastasis when SLNB was negative was estimated by means of Bayes' theorem which incorporated the pre-test probability and sensitivity and specificity of SLNB.
RESULTS: Axillary nodal metastasis was observed in 6.1% of T1a-b, 25.1% of T1c, 28.7% of T2, 35.0% of T3 tumors. Point estimates for the probability of nodal involvement when SLNB was negative ranged from 0.3-1.3% for T1a-b, 1.6-6.3% for T1c, 2.0-7.5% for T2, and 2.6-9.7% for T3 tumors with representative sensitivities of 80%, 85%, 90% and 95%, respectively. The risk may be higher when the tumor involves the upper outer quadrant of the breast, while it may be lower for an underweight woman.
CONCLUSIONS: The probability of axillary lymph node metastasis when SLNB is negative can be estimated using a Bayesian approach. Presenting the probability to the patient may guide the decision of surgery without conventional ALND.

Entities:  

Mesh:

Year:  2005        PMID: 16110290     DOI: 10.2325/jbcs.12.203

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  4 in total

1.  Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review.

Authors:  Idam de Oliveira-Junior; Eliana Aguiar Petri Nahas; Ana Cristina Cherem; Jorge Nahas-Neto; René Aloisio da Costa Vieira
Journal:  Breast Care (Basel)       Date:  2020-03-27       Impact factor: 2.860

2.  Tumor characteristics influencing non-sentinel lymph node involvement in clinically node negative patients with breast cancer.

Authors:  Gunay Gurleyik; Fugen Aker; Ali Aktekin; Abdullah Saglam
Journal:  J Breast Cancer       Date:  2011-06-18       Impact factor: 3.588

3.  Development of a clinical decision model for thyroid nodules.

Authors:  Alexander Stojadinovic; George E Peoples; Steven K Libutti; Leonard R Henry; John Eberhardt; Robin S Howard; David Gur; Eric A Elster; Aviram Nissan
Journal:  BMC Surg       Date:  2009-08-10       Impact factor: 2.102

4.  Modelling the probability of erroneous negative lymph node staging in patients with colon cancer.

Authors:  Carlos Fortea-Sanchis; Erica Forcadell-Comes; David Martínez-Ramos; Javier Escrig-Sos
Journal:  Cancer Commun (Lond)       Date:  2019-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.